Clinical Trial

An Exploratory Clinical Study of the Efficiency and Safety of TH027 in the Treatment of Relapsed/Refractory Solid Tumors

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase l, Open-Label, Dose-escalation Study to Evaluate the Safety, Tolerabilityand Antitumor Activity of TH027 CAR-T Cell lnjection (TH-CART-027) in Subjects With Relapsed or Refractory Solid Tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-26.
Trial Details
NCT Number NCT06951425
Lead Sponsor Shanghai Tongji Hospital, Tongji University School of Medicine
Collaborators: ThinkingBiomed
Conditions Solid Tumors
Enrollment 24 participants
Start Date 2025-06-01
Primary Completion 2028-11-30 (estimated)
Study Completion 2028-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-13